Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
459 studies found for:    myelodysplastic syndrome | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
2 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine
3 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
4 Unknown  Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis
5 Recruiting An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions: Drug: Azacitidine;   Drug: Durvalumab
6 Unknown  Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
7 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
8 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
9 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
10 Recruiting Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: CC-486 (ORAL AZACITIDINE);   Drug: Durvalumab
11 Recruiting The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
Condition: Myelodysplastic Syndromes (MDS)
12 Unknown  A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Decitabine Injection
13 Recruiting Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Conditions: Acute Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Interventions: Other: Blood sampling;   Other: Bone marrow aspirate;   Other: Skin biopsy;   Other: Buccal swab
14 Recruiting Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
Conditions: Adult;   Myelodysplastic Syndromes
Interventions: Other: questionnaire administration;   Other: fatigue assessment and management;   Other: observation;   Other: quality-of-life assessment
15 Unknown  Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: Bortezomib
16 Recruiting Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Biological: MEDI4736 Evaluate MEDI4736 in MDS;   Drug: VIDAZA;   Biological: tremelimumab
17 Recruiting 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Azacitidine
18 Not yet recruiting Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
19 Unknown  Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy
Condition: Myelodysplastic Syndrome
Interventions: Drug: BSC;   Drug: HIDRA/VPA
20 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years